Latest Ai In Healthcare News

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Pathkey.AI has completed a strategic review, bolstered its leadership team, and secured $3.5 million in funding to accelerate growth and broaden its AI platform's applications beyond clinical trials.

Enlitic, Inc. reported its strongest quarter yet with record contract wins totalling A$4.3 million, alongside a strategic capital raise and new cost-saving measures to fuel growth.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Enlitic has locked in commitments for an A$8 million convertible note capital raise, with initial funds arriving immediately and the remainder pending shareholder approval. This funding aims to extend the company’s runway as it advances its AI-driven healthcare solutions.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

Vection Technologies reports a record quarter-to-date cash intake of approximately $14 million and a robust $50 million forward pipeline, underscoring strong momentum across defence, AI, healthcare, and retail sectors.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

Beamtree Holdings has reported a 9% increase in recurring revenue for Q1 FY26, driven by strong contract wins and international expansion, including a key UK NHS partnership and a new autonomous coding rollout.

CurveBeam AI has received $5.6 million of its $6.5 million placement, issuing shares for the settled tranche while awaiting the remaining offshore transfer. The company plans to complete the share issuance once the final funds arrive.